Tag: AB2 Bio

Manufacturing, Research and Development

AB2 Bio and WuXi Biologics Collaborate on Orphan Drug Manufacture

October 30, 2020

Via: Genetic Engineering and Biotechnology News

AB2 Bio, a Swiss clinical-stage biotech company developing therapies for the treatment of severe systemic autoinflammatory diseases, and WuXi Biologics agreed to collaborate to set up and accelerate commercial-scale manufacturing of Tadekinig alfa, AB2 Bio’s recombinant IL-18 binding protein. AB2 […]